Oral glutamine supplementation reduces radiotherapyinduced esophagitis in lung cancer patients

Background: The purpose of this study was to assess the the efficacy of oral glutamine (GLN) in prevention of acute radiation-induced esophagitis in patients with lung cancer and determine the predictive role of clinical and dosimetric parameters. Materials and Methods: Thirty-two patients diagnosed with lung cancer were studied prospectively. Sixteen patients (50%) received prophylactic powdered GLN orally in doses of 10g/8h. Patients were treated 2 Gy per fraction daily, 5 days a week. We evaluated the grading of esophagitis daily at the end of each fraction of each treatment day until a cumulative dose of 50 Gy was reached. The primary end point was radiation-induced esophagitis. Results: All patients tolerated GLN well. Toxicity grade, weight loss, serum cytokine levels and esophageal transit times exhibited statistically significant improvement in the GLN receiving group. GLN suppressed the inflammation related to the disease and treatment and reduced toxicity with statistical significance. Conclusions: This study suggests a benefical role of oral GLN use in prevention and/or delay of radiation-induced esophagitis, in terms of esophageal transit time and serum immunological parameters, as well as weight loss

The relationship between hormone receptor status and c-erbb-2 level with treatment results of 640 breast cancer patients

Amaç: Çalışmada meme kanseri seyrini etkileyebilen hormon reseptör durumu ve c-erbB-2 düzeylerinin tedavi sonuçları üzerine olan etkileri saptanmaya çalışılmıştır. Yöntemler: Küratif amaçla tedavi uygulanan 640 meme kanserli hastada genel ve hastalıksız sağkalım verileri incelenmiştir. Ortalama takip 59,1 ay’dır.Hastalarda SPSS 16.0 versiyonunda Kaplan-Meier yöntemiyle genel ve hastalıksız sağkalım oranları, Log-Rank testi ile prognostik faktörlerin etkileri değerlendirilmiştir. Bulgular: ER (+) ve (-) olgularda sırasıyla beş yıllık genel sağkalım oranları %85,7, %71,2 (p<0,001), hastalıksız sağkalım oranları %79,9, %63,7 (p<0,001); PR (+) ve (-) hastalarda sırasıyla beş yıllık genel sağkalım oranları %85,6, %71,6 (p<0,001), hastalıksız sağkalım oranları %79,6, %64,3 (p<0,001) olarak bulunmuştur. ER ve PR pozitifliğinin genel ve hastalıksız sağkalımı anlamlı derecede arttırdıkları saptanmıştır. C-erbB-2 aşırı salınımında, negatiflere göre sırasıyla beş yıllık genel sağkalımda %76,4, %85,3 (p=0,002), hastalıksız sağkalımda %69,7, %79,1’lik (p=0,012) oranlar elde edilmiştir. En kötü prognostik grubun ER (-), PR (-), c-erbB-2 (+) hastalar olduğu gösterilmiştir. Sonuç: ER, PR ve c-erbB-2 düzeylerinin meme kanserinde büyük önem arz ettiği gösterilmiş ve hasta takiplerinde dikkat edilmesi gereken faktörler olduğu belirtilmiştir.Objective: In this study the relevant factors that effects the treatment outcomes of patients like hormone receptor and c-erbB-2 was established. Methods: The overall and disease-free survival rates were evaluated in 640 breast cancer patients. The mean follow-up was 59,1 months. Overall and disease-free survival rates found by Kaplan-Meier method at SPSS version 16.0. Log-Rank test evaluated the prognostic factors impact. Results: In ER (+) and (-) patients 5 year overall survival rates was 85,7%, 71,2% (p<0,001), disease free survival rates was 79,9%, 63,7% (p<0,001) respectively; in PR (+) and (-) patients 5 year overall survival rates was 85,6%, 71,6% (p<0,001), disease free survival rates was 79,6%, 64,3% (p<0,001) respectively. ER and PR positivity were significantly increased overall and disease-free survival. In c-erbB-2 over-expression 5 year overall survival rates was 76,4%, 85,3% (p=0,002), disease free survival rates was 69,7%, 79,1% (p=0,012) according to (-) patients. The worst prognosis had shown in ER (-), PR (-), c-erbB-2 (+) patients. Conclusion: ER, PR and c-erbB-2 levels have great importance in breast cancer and must be well considered in patients follow-up

The Comparision of Breast Cancer in the Young and Elderly Patients

OBJECTIV

Screening for Nutritional Status in Radiation Oncology Outpatients: TROD 12-01 Study

OBJECTIV